Diabetes

Previously approved for IV infusion.

Reduces risk for heart failure and cardiovascular disease hospitalizations.

Tips for identifying patients with diabetes who need more direction and help.

Noteworthy diabetes management products and updates making waves this year.

New CGM eliminates fingersticks, introduces new data presentation.

Now approved for risk reductions in patients with type 2 diabetes mellitus.

Now approved in 7mg and 14 mg tablets.

Cost, education, self-monitoring, and more. 

First non-insulin drug for pediatric use approved in nearly 20 years.

Type 2 diabetes mellitus is a risk factor for incident heart failure, according to a new scientific statement from the American Heart Association (AHA), and it increases the risk of morbidity and mortality in patients with established disease.

Originally approved in 2011, aflibercept is a vascular endothelial growth factor (VEGF) inhibitor.

How pipeline promises-and disappointments-are impacting patients with diabetes.

New drug combines dapagliflozin, saxagliptin, and metformin.

Results from a recent ELLIPSE trial indicate superiority in reducing blood sugar when compared to the placebo.

Increase adherence by matching technology to each patient's unique needs.

Consumers are using test strips that might lead to inaccurate results. 

Eli Lilly creates generic Humalog priced 50% lower 

Rounding up the news you need to know to start the new year.

GPS-based dietary prompts, continuous glucose monitors among the devices poised to revolutionize diabetes treatment and patient management. 

Drug Topics spoke to several community pharmacists  about their diabetes education programs and how they can be a revenue stream. Here’s their advice for other pharmacists.

A study has found that pharmacists in primary care networks can help lower A1c levels. 

Diets that involve fasting could impair the action of insulin and increase the risk of developing diabetes.

Some patients with type 2 diabetes and chronic kidney disease can be safely treated with metformin. 

High levels of vitamin D, 50 ng/ml, have been linked to a lower incidence of diabetes in a long-term study.

Insulin glargine should not be used past 28 days after the vial is first used, but 80% of patients do. 

Diabetes drug empagliflozin reduces fat levels in type 2 patients, which may reduce risk of severe liver disease.

Missing teeth could be a signal that diabetes may be developing.

The immune system could play a beneficial role in regulating insulin, according to a study from Switzerland.

Patients will soon have one less option when selecting insulin.